# US 2026/0091026 A1 · Methods of treating inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091026 A1
- Document ID: US20260091026A1
- Status: Published application
- Kind: A1
- Application number: 19/411,055
- Filed: 2025-12-05
- Published: 2026-04-02
- Earliest claimed: 2023-06-09
- Assignees: Interline Therapeutics, Inc.
- Applicants: Interline Therapeutics, Inc.
- Inventors: Robert Joseph MOREAU; Naomi S. RAJAPAKSA; David C. TULLY; Mario G. CARDOZO; Zuojun GUO; Meera RAO; Steffen GREßIES; Kai THEDE; Zachary K. SWEENEY
- Web page: https://patentgrep.com/patent/US20260091026A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present application relates to compounds of Formula (I) and Formula (II), as defined herein, and pharmaceutically acceptable salts thereof, and compositions comprising same. Also described are methods of treating the diseases and disorders disclosed herein, with the compounds of Formula (I) or Formula (II), and pharmaceutically acceptable salts of the foregoing, and the compositions comprising same.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt of either of the foregoing, wherein:
R1 is a 5-10 membered heteroaryl optionally substituted with 1-3 substituents independently selected from C1-C6 alkyl, C1-C6 thioalkyl, C1-C6 alkoxy optionally substituted with hydroxyl, —S(O2) C1-C6 alkyl, NR1AR1B, 4-10 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from halogen and C1-C6 alkyl, —(NH)—C1-C6 alkyl, and —(NH)-4-10 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from halogen and C1-C6 alkyl;
R1A and R1B are independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl;
R2A is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxyalkyl, C1-C6 hydroxyalkyl optionally substituted with 1 or 2 halogens, C3-C6 cycloalkyl, 4-10 membered heterocyclyl optionally substituted with 1 or 2 substituents independently selected from halogen, C1-C6 alkyl, and C(═O) OC1-C6 alkyl;
R3 is hydrogen or halogen;
X is selected from
R4 is hydrogen or C1-C6 alkyl;
R5 is selected from:
(i) C1-C6 alkyl optionally substituted with 1-4 substituents independently selected from:
(a) C3-C6 cycloalkyl optionally substituted with 1-3 substituents independently from halogen or phenyl,
(b) phenyl optionally substituted with 1-3 substituents independently selected from halogen, C1-C6 alkoxy, C1-C6 hydroxyalkyl, and cyano,
(c) —NRARB,
(d) hydroxyl,
(e) halogen,
(f) 4-10 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from benzyl, C1-C6 alkyl, and phenyl optionally substituted with C1-C6 alkyl, and
(g) 5-10 membered heteroaryl optionally substituted with 1-3 substituents independently selected from halogen, cyano, C1-C6 alkyl, and C1-C6 alkoxy;
(ii) C3-C10 cycloalkyl optionally substituted with 1-3 substituents independently selected from halogen, hydroxyl, C1-C6 alkyl, phenyl optionally substituted with 1-2 independently selected halogen and 5-10 membered heteroaryl;
(iii) 4-10 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from benzyl, C1-C6 alkyl, C3-C10 cycloalkyl, and phenyl optionally substituted with C1-C6 alkyl;
(iv) phenyl optionally substituted with 1-3 substituents independently selected from halogen, nitro, and C1-C6 haloalkyl;
(v) 5-10 membered heteroaryl optionally substituted with 1-3 substituents independently selected from halogen and C1-C6 alkyl;
(vi) C1-C6 alkoxy; or
(vii) C3-C6 cycloalkoxy;
or R4 and R5 with the atom to which they are attached together form a 5-12 membered heterocyclyl or 9-10 membered heteroaryl each optionally substituted with phenyl; and
RA and RB are independently selected from hydrogen and C1-C6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-a):
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-b):
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-c):
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-d):
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-e):
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-f):
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-g):
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-h):
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-i):
or a pharmaceutically acceptable salt thereof; wherein:
R1C is C1-C6 alkoxy optionally substituted with hydroxyl;
R1D is —S(O2)—C1-C6 alkyl;
R2A1 is C1-C3 alkyl or C3-C4 cycloalkyl; and
R5A is phenyl optionally substituted with halogen or C1-C6 alkyl; or 5-6 membered heteroaryl optionally substituted with halogen or C1-C6 alkyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein Formula (I) is (I-j):
or a pharmaceutically acceptable salt thereof, wherein:
R1E is a 5-10 membered heteroaryl substituted with 2 substituents independently selected from C1-C6 alkyl, C1-C6 thioalkyl, C1-C6 alkoxy optionally substituted with hydroxyl, and —S(O2) C1-C6 alkyl;
R2A1 is C1-C3 alkyl or C3-C4 cycloalkyl; and
Ring B is (i) phenyl optionally substituted with 1-3 substituents independently selected from halogen, C1-C6 alkoxy, C1-C6 hydroxyalkyl, and cyano; or (ii) 5-6 membered heteroaryl optionally substituted with 1-3 substituents independently selected from halogen, cyano, C1-C6 alkyl, and C1-C6 alkoxy.

### Claim 12

A compound selected from the group consisting of the compounds in Examples 1-194, or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating a RIPK2-associated disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating inflammatory bowel disease in a subject in need thereof, comprising administering to the subject an effective amount of the compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating inflammatory bowel disease in a subject in need thereof, comprising (a) determining that the subject is suffering from inflammatory bowel disease; and (b) administering to the subject an effective amount of the compound of the compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating inflammatory bowel disease in a subject previously identified or diagnosed as having inflammatory bowel disease, the method comprising administering to the subject an effective amount of the compound of the compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating Crohn's disease in a subject in need thereof, comprising administering to the subject an effective amount of the compound of the compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating Crohn's disease in a subject in need thereof, comprising (a) determining that the subject is suffering from Crohn's disease; and (b) administering to the subject an effective amount of the compound of the compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of treating Crohn's disease in a subject previously identified or diagnosed as having Crohn's disease, the method comprising administering to the subject an effective amount of the compound of the compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 13.
